TAK

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: TEVA RDY VTRS BMY GSK PRGO BHC GILD OGN

| Held by: FVD PPH IDVO AVDE APIE VEU BDYN JSTC AADR GINX

Scroll to Statements

Index	-	P/E	40.07	EPS (ttm)	0.41	Insider Own	0.00%	Shs Outstand	3.16B	Perf Week	-2.17%
Market Cap	51.35B	Forward P/E	25.39	EPS next Y	0.64	Insider Trans	-	Shs Float	3.16B	Perf Month	-2.40%
Enterprise Value	78.30B	PEG	0.79	EPS next Q	0.19	Inst Own	3.12%	Short Float	0.16%	Perf Quarter	-13.56%
Income	1.30B	P/S	1.72	EPS this Y	19.27%	Inst Trans	-0.51%	Short Ratio	1.71	Perf Half Y	15.33%
Sales	29.91B	P/B	1.05	EPS next Y	39.42%	ROA	1.35%	Short Interest	5.00M	Perf YTD	4.23%
Book/sh	15.46	P/C	13.73	EPS next 5Y	32.20%	ROE	2.72%	52W High	18.90 -14.00%	Perf Year	12.77%
Cash/sh	1.18	P/FCF	10.18	EPS past 3/5Y	-18.78% -18.66%	ROIC	1.70%	52W Low	12.99 25.10%	Perf 3Y	-1.04%
Dividend Est.	0.65 (3.99%)	EV/EBITDA	9.16	Sales past 3/5Y	0.19% -0.17%	Gross Margin	51.07%	Volatility	1.27% 1.32%	Perf 5Y	-6.72%
Dividend TTM	0.62 (3.82%)	EV/Sales	2.62	EPS Y/Y TTM	83.79%	Oper. Margin	12.09%	ATR (14)	0.29	Perf 10Y	-23.48%
Dividend Ex-Date	Sep 30, 2025	Quick Ratio	0.70	Sales Y/Y TTM	-0.47%	Profit Margin	4.34%	RSI (14)	34.40	Recom	1.93
Dividend Gr. 3/5Y	3.45% -4.49%	Current Ratio	1.27	EPS Q/Q	76.87%	SMA20	-1.67%	Beta	-0.03	Target Price	19.03
Payout	153.42%	Debt/Eq	0.63	Sales Q/Q	0.93%	SMA50	-6.46%	Rel Volume	1.37	Prev Close	16.48
Employees	47455	LT Debt/Eq	0.56	Earnings	May 13 AMC	SMA200	1.91%	Avg Volume	2.92M	Price	16.25
IPO	Mar 06, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.75% -3.01%	Trades		Volume	4,011,245	Change	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-13-26	Resumed	Morgan Stanley	Overweight
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

May-20-26 07:15AM	Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict (Pharmaceutical Technology)
06:43AM	Immunovants potential autoimmune blockbuster; Waves RNA editing update (BioPharma Dive)
May-18-26 05:51PM	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda (Business Wire)
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive)
May-13-26 02:38AM	Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results (Business Wire)
08:00AM	Loading…
May-04-26 08:00AM	Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) (Business Wire)
Apr-14-26 08:02PM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Quartz)
Apr-06-26 07:07AM	FDA floats new clinical trial reforms; Takeda punts Denali brain drug (BioPharma Dive)
Mar-28-26 03:00PM	Takedas Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care (Business Wire)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
12:01PM	FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment (Insider Monkey)
Mar-02-26 02:00AM	Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Business Wire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-27-26 09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
Feb-26-26 08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
09:35AM	Loading…
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire)
Feb-23-26 07:39AM	Novo Nordisk flags board members for re-election amid restructuring efforts (Pharmaceutical Technology)
Feb-20-26 10:17AM	Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps (Benzinga)
Feb-19-26 12:00PM	Positive Phase 3 Data Demonstrate Potential for ENTYVIO (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis (Business Wire)
Feb-18-26 10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-11-26 04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
05:30AM	Takeda and Iambic announce $1.7bn deal to advance small molecule programmes (Pharmaceutical Technology)
03:15AM	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takedas Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 (Business Wire)
Feb-09-26 12:59PM	Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery (Benzinga)
08:07AM	Takeda deepens AI drug discovery push with $1.7 billion Iambic deal (Reuters)
03:00AM	Takeda, Iambic partner in latest pharma AI push (BioPharma Dive)
Jan-31-26 09:36AM	Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? (Insider Monkey)
Jan-29-26 09:11AM	Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control (Benzinga)
08:37AM	Loading…
08:37AM	Takeda Pharmaceutical Q3 Earnings Call Highlights (MarketBeat)
01:37AM	Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead (Business Wire)
Jan-28-26 07:48AM	CMS selects next batch of 15 high-cost medicines for third negotiation cycle (Pharmaceutical Technology)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
Jan-22-26 09:13AM	ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? (Zacks)
07:45AM	Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jan-15-26 06:19PM	JPM26: Matrix-M Technology is central to Novavaxs strategy (Pharmaceutical Technology)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 12:10AM	Ascentage: Partnership With Takeda Going Well (Bloomberg)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
06:50AM	Alumis soars as TYK2 drug hits mark in psoriasis trials (BioPharma Dive)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-19-25 07:00AM	Cambridge property takes novel approach to quality in life sciences sector (Facilities Dive)
Dec-18-25 04:45AM	Takeda says $4B TYK2 drug succeeds in large psoriasis studies (BioPharma Dive)
03:00AM	Takedas Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:19AM	Takeda and Innovent fulfil close conditions for ADC and IO therapies (Pharmaceutical Technology)
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-03-25 07:00AM	New Phase 3 Data Show Takedas Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization (Business Wire)
Oct-30-25 03:04AM	Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year (Business Wire)
Oct-22-25 06:33AM	Chinas Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion (The Wall Street Journal)
Oct-21-25 05:53AM	Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio (Insider Monkey)
Oct-10-25 11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
Sep-23-25 06:04PM	20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries (Business Wire)
Sep-17-25 05:45AM	5 Best High-Yield Dividend Stocks to Buy Now (Motley Fool)
Sep-16-25 08:00AM	Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran (Business Wire)
Sep-08-25 03:00AM	Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 (Business Wire)
Sep-05-25 08:45PM	U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease (Business Wire)
Aug-28-25 04:55AM	Takeda Pharmaceutical Company Limited (TAK) Advances ?d T Cell Cancer Treatments (Insider Monkey)
Aug-08-25 01:18AM	Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis (Newsfile)
Jul-30-25 02:41AM	Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression (Business Wire) -5.03%
Jul-21-25 04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:29PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
08:00AM	Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA Administration (Business Wire)
Jul-17-25 08:24AM	Improving Margins, Cash Flow Strength, and an Undervalued Opportunity (GuruFocus.com)
Jul-15-25 09:10AM	Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA (Insider Monkey)
Jul-14-25 03:00AM	Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 (Business Wire)
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jun-30-25 08:00AM	Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jun-27-25 08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-25-25 11:13AM	Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? (Zacks)
08:54AM	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? (Zacks)
03:07AM	Takeda Announces New Assignments of Directors (Business Wire)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-06-25 10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-04-25 04:47AM	EC approves Takeda ADC plus chemo for stage IIb Hodgkins lymphoma (Pharmaceutical Technology)
Jun-03-25 10:12AM	European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD (Business Wire)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 07:30AM	Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award (Business Wire)
May-14-25 05:03PM	The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 (Business Wire)
May-12-25 04:28AM	Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices (Bloomberg)
04:18AM	Trump Vows US Drug Price Cuts of Up to 80% in Industry Blow (Bloomberg)
May-09-25 03:00PM	Top 4 GARP Stocks With Attractive PEG Ratios to Watch (Zacks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks) -5.25%
02:36AM	Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress (Business Wire)
May-07-25 12:06PM	Takeda Pharmaceutical FY Earnings Preview (Seeking Alpha)
12:00PM	Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
09:15AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings (GuruFocus.com)
May-05-25 08:00AM	BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers (Business Wire)
May-02-25 11:40AM	TAK or DSNKY: Which Is the Better Value Stock Right Now? (Zacks)
May-01-25 01:22PM	Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? (Zacks)
Apr-30-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice (Zacks)
09:32AM	Best Value Stocks to Buy for April 30th (Zacks)
08:05AM	Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education (Business Wire)
08:05AM	Best Income Stocks to Buy for April 30th (Zacks)
04:46AM	New Strong Buy Stocks for April 30th (Zacks)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

PresidentMr. Christophe P. Weber

CFO & DirectorMr. Milano Furuta

Ph.D.Dr. Andrew S. Plump M.D.

Chair of Management BoardDr. Seigo Izumo

Member of Management BoardMr. Haruhiko Hirate

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Lauren Rusckowski Duprey	Chief Human Resources Officer	Dec 09 '25	Proposed Sale	14.22	29,619	421,182	Dec 09 06:05 AM
Teresa Marie Bitetti	President, Global Oncology Bus	Dec 05 '25	Proposed Sale	14.28	87,023	1,242,688	Dec 05 06:08 AM
Giles Richard Platford	President, Plasma-Derived Ther	Dec 04 '25	Proposed Sale	14.31	58,421	836,005	Dec 04 06:02 AM
Thomas Wozniewski	Global Manufacturing & Supply	Jul 09 '25	Proposed Sale	15.42	6,136	94,617	Jul 09 06:45 AM
Teresa Marie Bitetti	President, Global Oncology Bus	Jul 09 '25	Proposed Sale	15.42	52,649	811,848	Jul 09 06:43 AM
Ramona A Sequeira	President, Global Portfolio Di	Jul 09 '25	Proposed Sale	15.42	102,972	1,587,828	Jul 09 06:41 AM
Marcello Pignagnoli Agosti	Global Business Development Of	Jul 09 '25	Proposed Sale	15.42	18,622	287,151	Jul 09 06:38 AM
Lauren Rusckowski Duprey	Chief Human Resources Officer	Jul 09 '25	Proposed Sale	15.42	40,919	630,971	Jul 09 06:36 AM
Julie Kim	President, US Business Unit	Jul 09 '25	Proposed Sale	15.42	58,559	902,980	Jul 09 06:34 AM
Giles Richard Platford	President, Plasma-Derived Ther	Jul 09 '25	Proposed Sale	15.42	28,552	440,272	Jul 09 06:32 AM
Gabriele Ricci	Chief Data & Technology Office	Jul 09 '25	Proposed Sale	15.42	26,874	414,397	Jul 09 06:29 AM
Elaine Mary Shannon	Global Quality Officer	Jul 09 '25	Proposed Sale	15.42	4,477	69,035	Jul 09 06:26 AM
Christophe Pierre Weber	Chief Executive Officer	Jul 09 '25	Proposed Sale	15.42	34,857	537,495	Jul 09 06:23 AM
Andrew Plump	President, Research & Developm	Jul 09 '25	Proposed Sale	15.42	169,313	2,610,806	Jul 09 06:20 AM
Akiko Amakawa	Corporate Strategy Officer & C	Jul 09 '25	Proposed Sale	15.42	5,608	86,475	Jul 09 06:17 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your Finviz experience